Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)

NCT04973228 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

457

Enrollment

INDUSTRY

Sponsor class

Conditions

Seborrheic Dermatitis

Interventions

DRUG: Roflumilast Foam
DRUG: Vehicle Foam

Sponsor

Arcutis Biotherapeutics, Inc.